Secondary progressive


Also found in: Acronyms.

Secondary progressive

A pattern of symptoms of multiple sclerosis in which there are relapses and remissions, followed by more steady progression of symptoms.
Mentioned in: Multiple Sclerosis
References in periodicals archive ?
To investigate the potential of simvastatin in the progressive stage of MS, the MS-STAT trial randomly assigned 140 people with secondary progressive MS (aged 18-65 years) to receive either 80 mg of simvastatin or placebo for 2 years.
Data Source: This was a 3-year, randomized, placebo-controlled trial of 493 patients with primary or secondary progressive MS.
Abbreviations: CNS = central nervous system, DMA = disease-modifying agent, EDSS = Expanded Disability Status Scale, FDA = Food and Drug Administration, LSCVAMC = Louis Stokes Cleveland Department of Veterans Affairs Medical Center, MRI = magnetic resonance imaging, MS = multiple sclerosis, PPMS = primary progressive MS, RRMS = relapsing-remitting MS, SCI = spinal cord injury, SPMS = secondary progressive MS, VA = Department of Veterans Affairs.
BioMS is conducting ongoing pivotal clinical trials evaluating the ability of dirucotide to affect disease progression in patients with secondary progressive MS:
MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS
The purpose of this study was to examine perceived cognitive impairment in secondary progressive and relapsing-remitting MS and to examine the relationship between level of disability, age, number of years with MS and self-reported cognitive symptoms.
In a 24-month study of 149 patients, treatment had a significant impact on "prolonging time to first treated relapse and on delaying disability progression" in patients with secondary progressive or progressive relapsing MS, and a significant reduction in the number of treated relapses and new MS lesions on magnetic resonance imaging, the company said.
It has also now been licensed for those with secondary progressive MS, whose condition is gradually deteriorating rather than being affected by relapses and periods of recovery.
Beta-interferon was licensed for people with secondary progressive MS in February 1999.
But others have secondary progressive MS which is treatable with a new form of beta-interferon and to which the guidelines may not be applicable.
Over time, many people with relapsing MS will "convert" to secondary progressive MS and become increasingly disabled, without remission of symptoms.
This report provides information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with latest updates, and special features on late-stage and discontinued projects.

Full browser ?